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Polymorbidity (multimorbid)  
more than one disease in one patient 
 Most polymorbidity formation is completed by the age of 60  
 Most often in different combinations and varying degrees of 
clinical symptoms observed  
 atherosclerotic vascular disease of the heart and brain (ischemic heart 
disease (IHD), arteriosclerotic encephalopathy), symptomatic 
(atherosclerotic) arterial hypertension (hypertension)  
 lung emphysema  
 neoplastic processes in the lungs, digestive organs, skin  
 chronic gastritis with secretory insufficiency  
 diabetes mellitus 
 osteochondrosis, arthrosis  
 eye diseases (cataract, glaucoma), and others. 
                    OUR PATIENT 
 
 Woman, 75 years old  
 Location: city of regional subordination  
 Pensioner  
 Date of admission: September 2014 
COMPLAINTS 
 Sharp pressing chest pain during moderate physical and emotional 
stress, without irradiation, stopped after taking 1 tab. nitroglycerin  
 Transient increase in blood pressure to 150/80 mmHg, accompanied 
by headache in the neck, stopped by drugs (captopril or propranolol)  
 Periodic heartbeat with heart rate over 100 beats / min. Occurring 
without a clear connection with the provoking factors and 
accompanied by a lack of air  
 Moderate shortness of breath when walking up to 15-20 m, stopped 
after stoping 
 Swelling of the lower third of the lower legs in the evening, held in the 
morning after sleep  
 Numbness fingertips on both feet  
 Pain in the calf muscles when walking up to 50 m 
History of the disease 
 Since 1990, with the rise of blood pressure fluctuations up to 170-150 / 80 mm Hg 
(work BP 140/80 mm Hg )  
 Since the autumn of 2007 - ischemic heart disease, angina FC III, obliterating 
atherosclerosis of the lower extremities against type 2 diabetes, insulin is secondary. 
Repeatedly treated inpatient, outpatient constantly taking nitrates, beta-blockers, 
aspirin, insulin  
 November 2008 - femoropopliteal alloshunting for obliterating atherosclerosis of 
lower limb arteries  
 Repeatedly treated permanently for angina FC III-IV,  paroxysmal atrial fibrillation, 
outpatient antianginal medications without the full effect  
 2009 - renal artery bypass grafting  
 2010 - elyuting stenting (4 elyuting stents in the left anterior descending (LAD), 
diagonal branch (I DB), the circumflex branch (CB)) of coronary arteries  
 2011 - plastic stenting of left anterior descending (LAD) artery 
 2012 - stenting of one of the branches of the coronary arteries, unspecified  
 In connection with an increase in heart attacks admitted to a clinic 
LIFE HISTORY 
 Lives alone in an isolated apartment  
 two children  
 40 years experience of teaching, 20 years - the principal  
 1963 - encephalitis  
 From 1972 - Type 2 diabetes mellitus, insulin-dependent secondary (1972-1974 
Maninil (5-10 mg / d), since 1974 - Insulin (48 pcs. / d))  
 1980 - hysterectomy, appendectomy, removal of atheroma on the right hand  
 2009 - phacoemulsification in both eyes, surgery for retinal detachment  
 Osteochondrosis L3-L4, L4-L5, L5-S1, osteoarthritis of the right shoulder and knee 
joints unidentified ago  
 Viral hepatitis, tuberculosis, venereal diseases denied  
 Allergies to medications, food purged household chemicals are not noted  
 Do not smoke, does not drink alcohol  
 Family history is not burdened by coronary heart disease and hypertension 
PERFOMANCE STATUS 
 Condition is satisfactory, active growth, hight- 156 cm, weight - 65 kg ,  BMI= 26,7 kg/m2 
 Skin pale pink color  
 Peripheral lymph nodes: submandibular, axillary and inguinal lymph nodes of soft consistency, 
painless, moderately agile and not soldered to each other and the skin  
 Lobe of the thyroid is not palpable, the isthmus is palpated as a homogeneous smooth cross-
strand, 1 cm wide  
 Musculoskeletal system without features, pain during lumbosacral palpation  
 Above mild lung sounds, auscultation - weakened vesicular breathing in the lower divisions  
 Heart borders extended to the left, rhythmic activity, tachycardia (heart rate 95 bpm.). Heart 
tones are muted, accent II tone of the aorta. Systolic murmur diffuse from the epicenter of 
the aorta.  
 Blood pressure 140/80 mm Hg on hypotensive therapy  
 Abdomen normal size, sensitive to palpation. Liver at the costal margin, painless. Physiological - 
atendency to constipation, urination - within the age norm  
 Sign of a beating on the lumbar region is negative on both sides  
 Auscultation vessels without features  
 Pastiness of the lower third of the leg 
PLAN OF SURVEY MORE RECOMENDATION 
 Clinical analysis of blood  
 Clinical analysis of urine  
 Biochemical analysis of blood 
(bilirubin, ALT, glucose, creatinine, 
lipids)  
 Chest X-ray  
 ECG  
 Echocardiography  
 Ultrasound of abdomen  
 Radiography of the lumbosacral 
and pelvic bones 
 glycemic profile  
 glycosylated hemoglobin  
 INR, electrolytes (Na, K)  
 ECG monitoring Holter + BP 
 consultation of ophthalmologist  
 consultation of endocrinologist 
(insulin titration)  
 consultation of nephrologist  
 Sigmoidoscopy (verification of 
chronic colitis) 
CLINICAL ANALYSIS OF BLOOD (09/30/14) 
MEASURE RESULT RATE (g) 
Hemoglobin 138 g / l F 120 - 140 g / l 
Erythrocytes 4.35 T / L F 3.9 - 4.7 T / L 
Color index 0,9 0,85 – 1,15 
Leukocytes 5.7 g / L 4,0 – 9,0 g/L 
ESR 10 mm / h 2-15mm/h 
Stable Neutrophil 2% 1-6 % 
Segmented Neutrophile 71% 47-72 % 
Eosinophils 2% 0,5-5,0% 
Basophils 0.5 1-1,0 % 
Lymphocytes 24% 19-37% 
Monocytes 8% 3-11 % 
Platelets 261 g / l 160-320 g/L 
Hematocrit 40,4% 36-42% 
All figures are in the normal range 
CLINICAL ANALYSIS OF URINE (09/30/14) 
MEASURE RESULT NORMAL RANGE  
Applies. DENSITY 1,009 1,001-1,040 
REACTION 6,0 5,0-7,0 
PROTEIN Not detected to 0.033 g / l 
GLUCOSE Not detected absent 
LEUCOCYTES 1-2 6-8 
EPITHELIUM 
TRANSITION 
Not detected 
BACTERIA Not detected 
All figures are in the normal range 
BIOCHEMICAL ANALYSIS OF BLOOD 
(30/09/14) 
MEASURE RESULT  NORMAL RANGE  
The total bilirubin 6.53 mmol / l 1,7-21,0 mmol/L 
Alanine aminotransferase 23 u/L <31 u/L 
Creatinine 101.5 mol / L 53-97 mol / L 
Glucose 10,39 mol / L 4,2-6,1 mmol / L 
Creatinine clearance by Cockcroft -Golt = 52 ml / min (≥90 ml / min) 
Hypercreatininemia, hyperglycemia 
BLOOD LIPID SPECTRUM (09/30/14) 
MEASURE RESULT NORMAL RANGE  
TOTAL CHOLESTEROL 4,58 mmol/l ≤ 5,2 mmol / l 
VLDL 0,81 mmol/l <1,0 mmol/l 
LDL 1,93 mmol/l <3,5 mmol/l 
HDL- cholesterol levels 1,84 mmol/l ≤ 0,9 mmol / l 
Triglycerides 1,80 mmol/l <2,3 mmol/l 
COEFFICIENT atherogenic 1,48 mmol/l To 3,0 mmol/l 
All figures are in the normal range 
ECG (29.09.14) 
Atrial flutter, tachysystolic form with holding 2: 1. HR = 111 bpm. Signs of left 
ventricular hypertrophy. Violation of repolarization in the anterior-posterior-lateral 
parts of the left ventricle 
ECG (30.09.14) 
Sinus rhythm, regular. Deviation EOS left. Violation of repolarization in 
the anterior wall of the left ventricle. Left ventricular hypertrophy 
ECHOCARDIOGRAPHY (1.10.14) 
 Aorta: increased aortic wall density, thickened, calcification, the valve opening of 12.9 (17.3 
mm)  
 The left ventricle: posterior wall thickness in diastole 15.2 (6-11 mm), the interventricular 
septum - 14.7 (6-11 mm), ejection fraction - 55% (55-80%). Mitral valve: elevated flap density, 
thickened, calcification, reversing, posterior flap movement sharply limited,  opening amplitude 
-19.3 (26-35 mm), diastolic velocity cover -30.0 (50-180) cm / s  
 The diameter of the right ventricle 25.2 (32 mm). Tricuspid valve regurgitation-II stage.  
 Anterior-posterior left atrial size 42 (13-37 mm), right - 40.6 mm (13-37 mm)  
 Pulmonary valve - regurgitation I st.  
 
Sclerotic changes in the walls of the aorta, fibrosis and calcification of the aortic and mitral valves, 
aortic valve stenosis.  
Stenosis of the left atrioventricular orifice mild.  
Left ventricular hypertrophy on the concentric type.  
Dilatation of both atria.  
Tricuspid regurgitation II item 
CHEST X-RAY (08/10/14) 
 Focal and infiltrative changes in the lungs were not 
identified. Signs of venous hypertension. Diffuse 
pulmonary fibrosis. Roots structurally enhanced by 
vascular component. Right sinus obliterated. Heart 
aortic configuration, extended to the left. Aorta is 
sclerotic in the arcus region. 
ULTRASOUND OF ABDOMEN (1.10.14) 
 Diffuse changes in the liver parenchyma and pancreas 
without magnification.  
      Cholesterosis gallbladder.  
      Microcalculosis in kidney.  
      Right-hydrocalicosis. 
X-RAY lumbosacral department 
(1.10.14) 
 Diffuse osteoporosis  
 Left-sided scoliosis  
 Osteochondrosis L5-S1 with spondyloarthrosis  
 Spondylosis deformans 
 Fragmented vascular calcification 
X-RAY of the pelvis (1.10.14) 
 Degenerative-dystrophic changes in the hip joints to 
osteoporosis 
BASIC CLINICAL SYNDROMES 1 
 Atherosclerosis is a systemic atherosclerosis with aortic stenosis, coronary 
artery disease, atherosclerotic stenosis of the left atrioventricular valve, 
atherosclerosis of the renal arteries and arteries of the lower extremites 
with bypass surgery, fragmentary vascular calcification of pelvic  
 Chronic coronary insufficiency (angina of effort FC III), elyuting stenting 
anterior descending (AD), diagonal branch (DB), the circumflex branch (5 
stents 2010-2012))  
 Isolated systolic hypertension stage III of I degree: left ventricular 
hypertrophy on the concentric type, SBP 150 mm Hg, diastolic blood 
pressure 80 mm Hg, atrial dilatation  
 Arrhythmic syndrome (persistant atrial fibrillation, atrial flutter)  
 Chronic heart failure (CHF), stage II FC III 
BASIC CLINICAL SYNDROMES 2 
 Phacoemulsification in both eyes, surgery for retinal detachment  
 Hyperglycemic syndrome (diabetes type II second insulin Propagation-step 
sub compensation, the average severity)  
 Chronic renal failure (creatinine clearance 52 mL / min)  
 Overweight: BMI = 26.7 kg / m 2  
 Articular syndrome (left-sided scoliosis, osteochondrosis and 
spondiloarthrosis L5-S1, spondylosis deformans, coxarthrosis)  
 Syndrome disturbances in motor function of the colon hypokinetic type 
(constipation) 
The left coronary artery The right coronary artery  
HEART BLOOD SUPPLY (according to coronary 
angiography) 
1 - RCA (right coronary artery)  
2 - PIB(posterior interventricular branch)  
3 -  (a branch of the sharp edge)  
interventricular branch) 
1 - the mouth of the left main coronary artery  
2 - LCA  
3 - LAD (left anterior descending branch)  
4 - DB (diagonal branch)  
5 –CB (circumflex branch)  
6 – OMB (obtuse marginal branch)  
7 - PIB (posterior interventricular branch) 
HEART BLOOD SUPPLY 
 The left coronary artery (LCA) supplies the left atrium, the 
entire front and larger part of the rear wall of the left ventricle, 
the anterior wall of the right ventricle and the front two thirds 
of the interventricular septum.  
 Right coronary artery (RCA) supplies the right atrium of the 
front and the entire back wall of the right ventricle, a small 
portion of the rear wall of the left ventricle, atrial septal, 
posterior third of the interventricular septum, papillary muscles 
of the ventricles.  
 Type of blood supply to the heart is determined by the artery, 
forming a posterior descending branch and supplies the lower 
rear wall of the left ventricle and the AV node. The "right" type 
A (RCA) blood supply occurs in 70% of people. "Left" type 
(LCA) of blood supply - 20% of people 
CLASSIFICATION OF IND  
(WHO, 1979; Ukrainian Heart Association Recomendations, 2011) 
 1 sudden cardiac death.  
       1.1. Clinical sudden coronary death with successful resuscitation.  
       1.2. Sudden cardiac death (death)  In case-based development of acute coronary 
insufficiency or acute myocardial infarction (code I 24.8 or I 22 to ICD-X).  
   2 Angina (code I 20 ICD-X).  
        2.1. Stable angina (indicating the FC I-IV according to the classification of the 
Canadian Cardiovascular Society), in patients with FC IV angina low voltages can be 
clinically manifested as angina at rest (code I 20.8 ICD-X).  
        2.2. Vasospastic angina (angiospastic, spontaneous, Prinzmetal variant (code I 
20.1. ICD-X).  
   3 Unstable angina (code I 20.0 ICD-X).  
        3.1. Angina, which occurred for the first time (the first appearance of life in 
angina attacks with transient ECG changes at rest to 28 days).  
        3.2. Progressive angina.  
        3.3. Early post-infarction angina (from 3 to 28 days). 
ANGINA FUNCTIONAL CLASS 
 (Classification of Canadian Cardiovascular Society, 1976. 
Recommendations Ukrainian Heart Association, 2011) 
FC Characteristics 
I Usual level of physical activity does not cause attacks 
angina ": for example, it does not occur during walking, climbing 
stairs. Angina developed with a significant, rapid or 
particularly long-term stress (force). 
II 
 
"Slight limitation of ordinary activity." angina  
occurs when walking fast or fast climbing stairs:  
walking on the rise; walking or climbing stairs after a meal; in  
cold or windy weather; under emotional stress; or  
only in the first hours after waking up. angina develops  
when walking at a distance> 2 blocks (>) on level ground,  
when climbing> 1 flight of ordinary stairs, at a normal pace, with  
normally 
III 
 
"A significant limitation of ordinary physical activity."  
Angina occurs when walking 1-2 blocks (<) on a flat  
areas, with the rise to 1 flight of ordinary stairs, in normal  
tempo under normal conditions 
IV 
 
"The failure to carry any physical activity without  
discomfort. Anginal symptoms may be present at rest 
CLASSIFICATION OF STAGES OF HYPERTENSION 
(Recommendations of Ukrainian Heart Association, 2008) 
stage The degree of target organ damage 
I 
 
Objective changes in the target organs are absent 
II 
 
There is no objective evidence of end-organ damage without symptoms with their  
hand or dysfunction:  
 left ventricular hypertrophy (on ECG, ultrasound, Ro);  
 generalized narrowing of the retinal arteries;  
 microalbuminuria and / or a small increase in the creatinine concentration (y  
m. - 115 - 133 mmol / l, y and. - 107 - 124 mmol / l);  
 carotid artery disease - a thickening of the intima-media> or the presence of  
atherosclerotic plaques 
III 
 
There is no objective evidence of end-organ damage with symptoms from their  
side and dysfunction  
• heart - myocardial infarction, heart failure, II A - III stage;  
• brain - a stroke, transient ischemic attack, acute hypertensive  
encephalopathy, vascular dementia;  
• fundus - hemorrhage and retinal exudates with papilledema  
the optic nerve or without;  
• Kidney - creatinine concentration in plasma in men> 133 mmol / l  
CLASSIFICATION OF HYPERTENSION by degree 
(Recommendations of the Association of Cardiologists of 
Ukraine, 2008) 
Category BP Systolic blood 
pressure (mm Hg.) 
Diastolic blood 
pressure (mm  
Hg) 
Optimal blood pressure < 120  
 
< 80  
 
Normal blood pressure < 130  
 
< 85  
 
High normal blood pressure 130-139 
 
85-89 
 
Mild hypertension (1 degree) 140-159 
 
90-99 
Moderate hypertension (grade 2) 160-179 
 
100-109 
 
Severe hypertension (grade 3) > 180 
 
> 100 
 
Isolation  
systolic hypertension 
> 140  
 
> 90  
 
RISK STRATIFICATION IN PATIENTS WITH 
HYPERTENSION (Recommendations of the Ukrainian 
Association of Cardiology, 2008) 
High additional risk 
ATRIAL FLUTTER AND FIBRILLATION CLASSIFICATION 
(HRS/EHRA/ECAS Expert Consensus Statement on Catheter and 
Surgical Ablation of Atrial Fibrillation, 2012; Recommendations 
of the Ukrainian Association of Cardiology, 2011 ) 
 For course 
           
 
 Paroxysmal (less than 7 days.) 
               Persistent (lasting more than 7 days) 
           
 
 Constant (there is a long, cardioversion is ineffective or not 
conducted) 

 
 As of the AV-holding 
           
 
 The correct form - regular 
           
 
 The irregular shape - irregular 

 
 According to the frequency of ventricular rhythm share: 
           
 
 Tachycardia option 
           
 
 Normal cardiac option 
           
 
 bradycardia option 
CLINICAL STAGES OF CHRONIC HEART FAILURE (CHF)  
(Stragesko N.D., Vasilenko N.H., 1935, Ukrainian Heart Association 
Guidelines for diagnosis, treatment and prevention of heart failure, 2013) 
stages clinical manifestations 
I Start, hidden, shown only on exertion as shortness of breath, tachycardia, 
excessive fatigue, expressed sharper and longer than that of a healthy person. 
Hemodynamics and organ function is not impaired; reduced ability to work 
II 
 
Signs of hemodynamic instability. Metabolic functions of other organs 
II A Failure of the right or left of the heart. Stagnation and dysfunction of other 
organs are mild and often appear to the end of the day or after exercise 
(disappear after a night's rest) 
II B Failure of the right and left heart. Stagnation of blood are more pronounced 
and occur at rest (do not disappear after a night's rest, may be slightly 
reduced) 
III Of course, the dystrophic heart failure with severe hemodynamic disorders, 
persistent metabolic and functions of all the organs, development of 
irreversible changes in the structure of organs and tissues, and disability. 
HEART FAILURE FUNCTIONAL CLASSES  
(NYHA 1964; Ukrainian Heart Association Guidelines for 
diagnosis, treatment and prevention of heart failure, 2013) 
 I. There is no limitation of physical activity  
 II. Light limitation of physical activity  
 III. A significant limitation of physical activity  
 IV. Inability to perform any physical  
 load without causing shortness of breath 
Variants CHF 
  
 1st variant. Systolic dysfunction 
the left ventricle: ejection fraction less than 
40%  
 2nd variant. Preserved systolic 
function: ejection fraction greater than 40% 
LEFT VENTRICULAR DYSFUNCTION VARIANT IN HF 
(Recommendations of the Ukrainian Association of Cardiology 
for the diagnosis, treatment and prevention of heart failure, 
2013) 
CHA2DS2-VASc score 
(ESC Guidelines for the management of atrial fibrillation, 2011) 
RISK FACTOR  points 
Stroke, TIA, or arterial embolism and anamnesis 2 
Age> 75 years 2 
hypertension 1 
Diabetes mellitus 1 
Heart failure, left ventricular dysfunction,  EF≤40% 1 
Vascular disease (myocardial infarction, peripheral atherosclerosis, 
plaque in the aorta) 
1 
Age 65-74 1 
Gender/ Female  1 
• The expected frequency of strokes according to the score in the year:  
• 0  1-2%  
• 2  4%  
• 4  8.5%  
• 6  18-27% 
HAS-BLED score 
(ESC Guidelines for the management of atrial fibrillation, 2011) 
RISK FACTOR  points 
Arterial hypertension (high SBP) 1 
Impaired Hepatic Function: heavy chronic disease or increased bilirubin ≥2 times 
the upper limit of normal in combination with increased AST / ALT ≥ 3 times the 
upper limit of normal 
1 
Impaired renal function: creatinine ratio ≥ 200, dialysis, transplantation 1 
Stroke 1 
Bleeding history or predisposition to it 1 
Labile INR (unstable or high in the therapeutic range less than 60% of the time) 1 
Age over 65 years 1 
Alcohol abuse 1 
Acceptance of others. Drugs that increase the risk of bleeding (NSAIDs, 
antiplatelet and out.) 
1 
Scale of assessment of bleeding: high risk for a sum score ≥ 3 
BODY MASS INDEX (WHO, 1997) 
Body mass deficit less than 18.5 
Normal body mass 18,5-24,9 
 
Excessive body mass 25-29,9 
 
Obesity I degree 30-34,9 
 
Obesity II degree 35-39,9 
 
Obesity III degree more than 40 
BMI = weight (kg) / height (m²) 
Classification of Diabetes Mellitus in severity 
(WHO, 1995) 
 Easy (I degree) - is characterized by a low level of blood glucose, which is less than 
8 mmol / l fasting small daily glycosuria (from trace to 20 g / l). Compensation 
condition is maintained by dietary intervention 
 
 At an average (second degree) of gravity - fasting blood glucose increased to 14 
mmol / L, blood glucose fluctuations throughout the day, daily glycosuria usually 
does not exceed 40 g / l, occasionally develops ketosis or ketoacidosis. Diabetes 
compensation is achieved by diet and oral hypoglycemic agents or insulin 
administration 
 
 Severe (III degree) form - characterized by high levels of blood glucose (fasting 
more than 14 mmol / l), significant fluctuations in blood sugar content during the 
day, a high level of glycosuria (more than 40-50 g / l). Patients require constant 
insulin dose of 60 ML and more, they have identified a variety of diabetic 
angioneuropathy . 
CLASSIFICATION OF DIABETES ON THE 
EXTENT glycemic control (WHO, 1995) 
 Phase compensation - good condition of the patient in whom 
treatment fails to reach normal levels of sugar in the blood and 
its complete absence in the urine  
 
 Phase subcompensation - unable to achieve such good results, 
but the blood glucose level is not much different from the 
normal, that is no more than 13.9 mmol / l, and the daily loss of 
the sugar in the urine is less than '50. Thus acetone in urine is 
absent 
 
 Phase decompensation - despite treatment, blood sugar rises 
more than 13.9 mmol / l and loss of glucose in the urine per 
night exceds 50 g, acetone in urine appears. Available 
hyperglycemic coma 
HEALTH FACILITY DIAGNOSIS 
 Main: CHD: stable angina FC III. Diffuse atherosclerosis of the 
coronary arteries. Elyuting stenting of the left anterior descending 
branch (LAD), diagonal branch (DB), the circumflex branch (CB) (5 
stents 2010-2012). Arterial hypertension stage II of III degree. The 
very high risk. HF I-IIa stage with preserved left ventricular pump 
function. Paroxysmal atrial fibrillation, atrial flutter, tachysystolic 
form, frequent supraventricular, rare ventricular premature beats. 
Atherosclerosis of lower limb arteries. Operation alloshunting of 
femoropopliteal-tibial segment vessels of the right leg (2008). Type 2 
diabetes, secondary insulin-dependent, severe form.  
 Related: lumbalgia due to degenerative disc disease L3-L4, L4-L5, 
L5-S1, spondylarthrosis, osteoporosis, recurrent, remission stage. 
Osteoarthritis of the right shoulder, knee joints. 
CLINICAL DIAGNOSIS 1 
 Main:  
Systemic atherosclerosis (atherosclerosis of the aorta, aortic stenosis, coronary 
atherosclerosis, atherosclerotic stenosis of the left atrioventricular valve, 
atherosclerosis of kidney, pelvic arteries and arteries of the lower limbs). 
Peripheral arterial disease: femoral-popliteal-tibial segment vessels of the right 
leg (2008), renal artery bypass surgery (2009)  
Coronary artery disease: stable exertional angina FC III. Isolated systolic 
hypertension stage III, soft power. High added risk. Persistant atrial 
fibrillation, atrial flutter, tachysystolic form. Elyuting stenting of the left 
anterior descending branch, I diagonal branch of the left coronary artery, the 
circumflex branch of the left coronary artery (5 stents 2010-2012). HAS-
BLED score of  2 points, CHА2DS2-VAS score of 6 points  
CHF stage II with preserved left ventricular pump function (ejection fraction = 
55%), III FC. 
CLINICAL DIAGNOSIS 2 
 Comorbid conditions  
Phacoemulsification in both eyes, surgery for retinal detachment 
(2009)  
Overweight: BMI = 26.7 kg / m 2  
Diabetes type 2 second insulin dependent step subcompensation 
average severity  
Irritable bowel syndrome with constipation predominance  
Chronic kidney disease stage 3. Chronic pyelonephritis, 
remission stage. USD  
Osteoarthrosis, polyosteoarthrosis of right shoulder, bilateral 
gonarthrosis, 0 activity, Ro III. Osteochondrosis of lumbar spine. 
FJD I stage 
DIFFERENCES IN DIAGNOSIS 
 Health facility diagnosis 
 
 Osteoarthritis of the right shoulder, 
knee joints 
 The clinical diagnosis  
 Systemic atherosclerosis (atherosclerosis of 
the aorta, aortic stenosis, coronary 
atherosclerosis, arteriosclerosis, stenosis of 
the left atriroventricular valve 
atherosclerosis of kidney, pelvic arteries 
and arteries of the lower limbs)  
 Isolated systolic hypertension stage III, soft 
power  
 Phacoemulsification in both eyes, surgery 
for retinal detachment  
 Overweight BMI = 26.7  
 Irritable bowel syndrome with constipation 
predominance  
 Chronic kidney disease stage 3. Chronic 
pyelonephritis, remission stage. USD 
TREATMENT  
 Lifestyle modification  
 Medical intervention 
Lifestyle modifications 
 1 Change in daily routine  

 
 The duration of sleep at least 8 hours a day  

 
 Daytime sleep for 1-2 hours  
 
 2 Control of body weight  

 
 Weigh at least 1 time per week  

 
 Weigh an empty stomach before breakfast, in the same clothes, no shoes  

 
 Record data in the table of self-control.  

 
 If necessary (as recommended by the attending physician) daily control of 
the amount you drink and the discharged liquid  

 
 An increase in the weight of 1 kg per day or 2-2.5 kg for 3-4 days - 
consultation with doctor 
Lifestyle modifications 
 3 Diet. Restriction of salt intake  

 
 Dieting agreed with the doctor: the food is easily digestible, low daily 
energy value (1400-1500 kcal), eat small portions 4-5 times a day, last meal 
3 hours before bedtime, limiting the admission of salt (no more than 2 T / 
day.), not an additional salt in food  

 
 Do not hold the salt shaker on the table to determine the amount of salt in 
the product use instructions on the package and a list of products with 
information about the salt content  

 
 Continuously monitor the volume of fluid consumed. At day should 
drinking from 1.5 to 2 liters of fluid. If necessary (on doctor's advice) is 
limited to the amount of fluid (up to 800 ml-1 liter per day) 
Lifestyle modifications 
 4 Nutrition for diabetes  
 
   The amount of energy in the diet should be equal to the energy needs of the patient.  
   Amount of protein, fat, carbohydrates should be balanced  
   Meal of the day - 5-6 times  
   All foods are divided into three groups: 
 
1 Products that can be used without restrictions. This group includes all vegetables except potato 
and maize (but made ​​with a minimum of fat) as well as tea, coffee, without the addition of cream 
and sugar  
2 Products that can be consumed in moderate amounts (half of the usual portions - that is, to eat 
half as much as usual). These products include lean meat, low-fat fish, low-fat dairy products, 
cheese, less than 30% fat, potatoes, corn, beans, bread, cereals, fruits, eggs  
3 Foods that should be excluded from the daily diet. This group includes foods that contain a lot 
of fat (butter, fatty meat, fish, meats, sausages, leather birds, canned cheese with a fat content of 
more than 30%, cream, sour cream, mayonnaise, nuts, seeds); sugar and sweets (confectionery, 
candy, chocolate, jam, jam, honey, soft drinks, ice cream) 
Lifestyle modifications 
 5 Regular exercise  
    

 
 Types of exercise, duration and intensity of the chosen physician, 
depending on the severity of heart failure, and other factors after the 
respective test  

 
 To start the load at a slow pace and increase it gradually  

 
 Plan for a period of rest before and after exercise to avoid excessive 
fatigue  

 
 Do not perform the exercise immediately after a meal, on a full stomach  

 
 Immediately stop the load when a feeling of fatigue  

 
 Completion exercise must also be gradual, to bring the body into a state 
close to the initial 
 HEALTH FACILITY TREATMENT 
 Β-adrenergic blokator- betaksalol (Lokren) 10 mg in the morning  
 Calcium antagonist, nifedipine (Koridipin retard) 20 mg at night  
 Antiplatelet agents:  
      - Acetylsalicylic acid (Aspirin-cardio) 100 mg 1 day;  
      - Clopidogrel (Plavix) 75 mg in the morning.  
 Statin-rosuvastatin (Roxera) 20 mg in the evening.  
 Class III antiarrhythmic drug amiodarone-(Cordarone) 200 mg 2 day.  
 Antianginal drug, isosorbide mononitrate 50 mg 1 day.  
 NSAID diclofenac sodium 3 ml / m  
 Anxiolytic-diazepam (Sibazon) 5 mg at night.  
 Metabolic means-thioctic acid (Valium) 600 mg / in the cap. №5.  
 Capillary growth stabilizes tool-quercetin with polyvinylpyrrolidone (Corvitin) 500 mg 1 day.  
 Nutrient stimulyator- gemoderivat deproteinized calf blood (Actovegin) 5.0 ml / in.  
 Medications for CVS -Mildrokard 10% 5,0 1 day.  
 Physiotherapy 
RECOMMENDED TREATMENT  1 
Systemic medication  
 Statins - rosuvastatin 20 mg 1 time per day  
 Antianginal drug - isosorbide mononitrate 50 mg 1 time per day. Nitroglycerin (tablets or spray) for the 
request 
 ACE inhibitor - ramipril 5 mg in the morning under the control of blood pressure  
 Class III antiarrhythmic drug - amiodarone scheme, under the control of heart rate, heart rate  
           - SR recovery - 400 mg 3 times / day  
           - Prevention of paroxysms - under the scheme: 1st week of -600 mg / day, 2nd week - 400 mg / day, 
4 weeks - 200 mg / day  
           - Maintenance dose - 100-200 mg / day  
 Anticoagulant - Warfarin, 5 mg / day according to the scheme; better - Dabigatran - 110 mg 1 p / day or 
Rivaroxaban - 10 mg p / day  
 Diuretic - torasemide 5 mg under the scheme in the morning before eating  
 insulin  
   short-acting Actrapid HM  
   long-acting Lantus  
 According to the scheme in the morning - a short d-I 8 units, long-acting - 12 units  
                   dinner - short d-I 8 units  
                   evening - short d-I 8 units, long-acting - 12 units 
RECOMMENDED TREATMENT 2 
 Local drug treatment (Nonsteroidal anti-inflammatory 
drugs- ointment locally)  
 Physiotherapy 
DIFFERENCES IN TREATMENT 
 Health facility treatment 
 Β-blocker - betaksalol (Lokren) 10 mg in the 
morning  
 Calcium antagonist, nifedipine (Koridipin -retard) 
20 mg at night  
 antiplatelet agents:  
      - Acetylsalicylic acid (Aspirin-cardio) 100 mg 
1 day RV;  
      - Clopidogrel (Plavix) 75 mg in the morning  
 NSAID diclofenac sodium 3 ml / m  
 Anxiolytic - diazepam (Sibazon) 5 mg at night.  
 Metabolic means - thioctic acid (Valium) 600 mg 
/ in the cap. №5.  
 Capillary growth stabilizes tool-quercetin with 
polyvinylpyrrolidone (Corvitin) 500 mg I / cap.  
 Biogenic stimulant - Despres teinizi Rowan 
gemoderivat calf blood (Actovegin) 5.0 ml / in. 
 Medications for CCC -Mildrokard 10% 5,0 / in. 
 The recommended treatment  
 Diuretic - Forasemide 5 mg under 
the scheme in the morning before 
eating  
 ACE inhibitor - Ramipril 5 mg in 
the morning under the control of 
blood pressure  
 Anticoagulant - Warfarin, 5 mg / 
day according to the scheme; 
better - Dabigatran - 110 mg 1 p / 
day or Rivaroxaban - 10 mg p / 
day 
PROGNOSIS 
 Prognosis for life - non-compliance with doctor's 
appointments - satisfactory  
 The prognosis for recovery - an unfavorable 
PREVENTION 
 Secondary:  
     Healthy lifestyle  
     Compliance with doctor's appointments 
THANK YOU  FOR ATTENTION  
